A number of firms have modified their ratings and price targets on shares of Cytokinetics (NASDAQ: CYTK) recently:

  • 9/9/2016 – Cytokinetics had its “buy” rating reaffirmed by analysts at FBR & Co.
  • 9/5/2016 – Cytokinetics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $12.00 price target on the stock. According to Zacks, “Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. “
  • 9/2/2016 – Cytokinetics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics’ lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. “
  • 9/1/2016 – Cytokinetics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $17.00 price target on the stock.
  • 8/18/2016 – Cytokinetics had its “buy” rating reaffirmed by analysts at Roth Capital. They now have a $22.00 price target on the stock.
  • 8/2/2016 – Cytokinetics had its “buy” rating reaffirmed by analysts at JMP Securities. They now have a $17.00 price target on the stock.
  • 7/27/2016 – Cytokinetics had its price target raised by analysts at Needham & Company LLC from $15.00 to $17.00. They now have a “buy” rating on the stock.

Cytokinetics, Inc. (NASDAQ:CYTK) traded up 0.34% during midday trading on Wednesday, reaching $8.85. The company had a trading volume of 233,911 shares. Cytokinetics, Inc. has a 12-month low of $6.00 and a 12-month high of $13.18. The stock has a 50-day moving average price of $11.03 and a 200 day moving average price of $8.98. The company’s market capitalization is $351.37 million.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.02. Cytokinetics had a negative return on equity of 69.51% and a negative net margin of 132.01%. Equities analysts forecast that Cytokinetics, Inc. will post ($1.30) EPS for the current year.

Cytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.

5 Day Chart for NASDAQ:CYTK

Receive News & Ratings for Cytokinetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.